India's largest drugmaker Ranbaxy Laboratories reported a consolidated net loss of Rs 951 crore for the financial year ended December 2008 compared with a net profit of Rs 774.58 crore the previous year, as per its audited results declared on Friday. The Gurgaon-based company's net sales grew 8.26% to Rs 7,295 crore in 2008, from Rs 6,692 crore in 2007.
The net loss for the year was 4% higher than the unaudited consolidated annual net loss of Rs 914 crore, announced in January. Hit by foreign exchange losses, ban on 30 drugs in the US and adoption of a new accounting standards, it had recorded one of its worst performances in 2008. Ranbaxy's scrip rose 4% to Rs 164.35 at the Bombay Stock Exchange (BSE). Under the audited figures, net sales were 6% higher at Rs 7,295 crore compared to the unaudited financials.
Ranbaxy has also appointed corporate lawyer Percy Shroff as an independent director on the board. "The board of directors of the company, at its meeting held on March 27, approved the appointment of Percy Shroff as a director (independent) of the company in the casual vacancy caused by the resignation of Harpal Singh," it informed the BSE on Friday.
Ranbaxy's CMD Malvinder Singh told ET: "We have appointed BSR & Co, the Indian affiliate of KPMG, as our auditor as KPMG is the global auditor of our parent company Daiichi Sankyo."
The drugmaker has also sought a waiver from the central government for the excess managerial remuneration paid last year. As per the previous auditor, Ranbaxy paid Rs 27.7 crore as managerial remuneration to its directors in 2008, which was in excess of the limits under the Companies Act. Had the company accounted for the remuneration in accordance with the Act, the company's loss after tax for the year would have been lower by Rs 18 crore, while its loans and advances have been higher by Rs 27 crore. |
Check out the all-new Messenger 9.0!
Click here.
|
Q3FY2009 Pharma earnings preview -
The pharmaceutical companies under our coverage are expected to report a 14.4% increase in their revenues for Q3FY2009. The expected growth of the pharmaceutical companies is lower than that seen in the previous quarters due to a general slowdown in the domestic market (the domestic market growth moderated to ~10.5% in Q3FY2009 as compared with ~12-14% in the preceding quarters) and the high-base of Q3FY2008 for companies such as Sun Pharmaceuticals (Sun Pharma) and Glenmark Pharmaceuticals (Glenmark). The Q3FY2008 revenues of these two companies were boosted by exclusivities and milestones respectively. With most companies having hedged a large part of their outstanding receivables at around the Rs41-42 level, the benefit of the weaker rupee would be only partial. Sun Pharma would be the biggest beneficiary of the weaker rupee, since it has not hedged aggressively at higher levels of the rupee, relying more on the natural hedge mechanism. -
The operating profit margin (OPM) of companies under our coverage is expected to shrink by 400 basis points, largely driven by a reduction in the margin of Sun Pharma (the Q3FY2008 margin was at an all-time high due to the Oxcarbazepine, Pantoprazole and Ethyol exclusivities) and Glenmark (which had recorded a very high margin in Q3FY2008 due to the receipt of a milestone income). A low top line growth would also result in margin pressure for companies like Ranbaxy Laboratories (Ranbaxy; the US Food and Drug Administration [USFDA] ban to lead to decline in US business) and Orchid Chemicals and Pharmaceuticals (Orchids; due to the absence of any significant new launches). On the other hand, we expect companies like Lupin and Piramal Healthcare (Piramal) to witness healthy margin expansion due to strong traction in revenues. We expect in input cost to largely remain stable on account of the negating influences of the weaker rupee and the lower prices of active pharmaceutical ingredients (APIs) and intermediates (due to the resumption of supplies from China, after the Beijing Olympics 2008). -
With a modest revenue growth and poor operating performance, the reported net profit of the companies under our coverage would decline by 23.7%. This would be on account of the marked-to-market (MTM) losses (owing to a ~3% depreciation in the Indian Rupee against the US Dollar) recorded by companies like Ranbaxy, Orchid, Cadila Healthcare (Cadila) and Ipca Laboratories (Ipca), which have outstanding foreign exchange (forex) liabilities. Higher interest and depreciation costs (due to acquisitions and/or expansion in capacities) would also affect the reported profits in the case of Lupin, Opto Circuits (Opto), Elder Pharmaceuticals (Elder) and Surya Pharmaceuticals (Surya). One-time incomes recorded in Q3FY2008 (in the case of Sun Pharma, Glenmark and Lupin) would also limit the net profit growth of these companies. Lupin's net profit growth would also be affected. On excluding the non-recurring income/expenses and the forex impact, we believe the adjusted net profit of the companies under our coverage would grow by ~30%. -
Our top picks include Sun Pharma, Piramal, Opto and Torrent Pharmaceuticals (Torrent), which are expected to deliver strong top line and bottom line growth. On the other hand, companies like Ranbaxy, Ipca and Orchid could surprise negatively due to higher than anticipated forex losses. -
The key risk to our estimates for Q3FY2009 is companies reporting MTM losses on hedging instruments or on foreign currency derivatives. We believe companies like Ranbaxy could have outstanding foreign currency hedges on which they could incur certain losses. |
|
|
Make sure your wardrobe reflects the latest trends and styles in the world of fashion.
Try it!
|
Q3FY2009 Pharma earnings preview -
The pharmaceutical companies under our coverage are expected to report a 14.4% increase in their revenues for Q3FY2009. The expected growth of the pharmaceutical companies is lower than that seen in the previous quarters due to a general slowdown in the domestic market (the domestic market growth moderated to ~10.5% in Q3FY2009 as compared with ~12-14% in the preceding quarters) and the high-base of Q3FY2008 for companies such as Sun Pharmaceuticals (Sun Pharma) and Glenmark Pharmaceuticals (Glenmark). The Q3FY2008 revenues of these two companies were boosted by exclusivities and milestones respectively. With most companies having hedged a large part of their outstanding receivables at around the Rs41-42 level, the benefit of the weaker rupee would be only partial. Sun Pharma would be the biggest beneficiary of the weaker rupee, since it has not hedged aggressively at higher levels of the rupee, relying more on the natural hedge mechanism. -
The operating profit margin (OPM) of companies under our coverage is expected to shrink by 400 basis points, largely driven by a reduction in the margin of Sun Pharma (the Q3FY2008 margin was at an all-time high due to the Oxcarbazepine, Pantoprazole and Ethyol exclusivities) and Glenmark (which had recorded a very high margin in Q3FY2008 due to the receipt of a milestone income). A low top line growth would also result in margin pressure for companies like Ranbaxy Laboratories (Ranbaxy; the US Food and Drug Administration [USFDA] ban to lead to decline in US business) and Orchid Chemicals and Pharmaceuticals (Orchids; due to the absence of any significant new launches). On the other hand, we expect companies like Lupin and Piramal Healthcare (Piramal) to witness healthy margin expansion due to strong traction in revenues. We expect in input cost to largely remain stable on account of the negating influences of the weaker rupee and the lower prices of active pharmaceutical ingredients (APIs) and intermediates (due to the resumption of supplies from China, after the Beijing Olympics 2008). -
With a modest revenue growth and poor operating performance, the reported net profit of the companies under our coverage would decline by 23.7%. This would be on account of the marked-to-market (MTM) losses (owing to a ~3% depreciation in the Indian Rupee against the US Dollar) recorded by companies like Ranbaxy, Orchid, Cadila Healthcare (Cadila) and Ipca Laboratories (Ipca), which have outstanding foreign exchange (forex) liabilities. Higher interest and depreciation costs (due to acquisitions and/or expansion in capacities) would also affect the reported profits in the case of Lupin, Opto Circuits (Opto), Elder Pharmaceuticals (Elder) and Surya Pharmaceuticals (Surya). One-time incomes recorded in Q3FY2008 (in the case of Sun Pharma, Glenmark and Lupin) would also limit the net profit growth of these companies. Lupin's net profit growth would also be affected. On excluding the non-recurring income/expenses and the forex impact, we believe the adjusted net profit of the companies under our coverage would grow by ~30%. -
Our top picks include Sun Pharma, Piramal, Opto and Torrent Pharmaceuticals (Torrent), which are expected to deliver strong top line and bottom line growth. On the other hand, companies like Ranbaxy, Ipca and Orchid could surprise negatively due to higher than anticipated forex losses. -
The key risk to our estimates for Q3FY2009 is companies reporting MTM losses on hedging instruments or on foreign currency derivatives. We believe companies like Ranbaxy could have outstanding foreign currency hedges on which they could incur certain losses. |
|
|
Make sure your wardrobe reflects the latest trends and styles in the world of fashion.
Try it!
Safe Harbor:
The information contained and provided on this Website provides Investment advice for the education of investors. The posts are an information service only. Recommendations, opinions or suggestions are given with the understanding that readers acting on this information assume all risks involved. We do not assume any responsibility or liability resulting from the use of such information, judgment and opinions for Trading or Investment purposes.